Search research articles
Contact Us
Filters
Showing results (11-20 of 70) with videos related to
Page
of 7
Sort By:
Journal of Atherosclerosis and Thrombosis
|
September 18, 2023
Long-term Efficacy and Safety of K-924 Pitavastatin/Ezetimibe Fixed-dose Combination in Patients with Hypercholesterolemia: A Phase III, Multi-center, Open-label Trial
Junya Ako, Koutaro Yokote, Kenichi Tsujita, et al.
Journal of Atherosclerosis and Thrombosis
|
April 10, 2018
Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Hidenori Arai, Shizuya Yamashita, Koutaro Yokote, et al.
Journal of Clinical Lipidology
|
December 6, 2017
Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial
Shun Ishibashi, Hidenori Arai, Koutaro Yokote, et al.
Endocrinology, Diabetes & Metabolism
|
November 21, 2023
Reductions in liver enzymes are associated with anti-hyperglycaemic and anti-obesity effects of tofogliflozin in people with type 2 diabetes: Post-hoc analyses
Toshinari Takamura, Kohei Kaku, Akihiro Yoshida, et al.
Atherosclerosis
|
April 16, 2017
Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia
Hidenori Arai, Shizuya Yamashita, Koutaro Yokote, et al.
Journal of Atherosclerosis and Thrombosis
|
March 13, 2023
Efficacy and Safety of Pitavastatin/Ezetimibe Fixed-Dose Combination vs. Pitavastatin: Phase III, Double-Blind, Randomized Controlled Trial
Kenichi Tsujita, Koutaro Yokote, Junya Ako, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
July 16, 2026
Pemafibrate Improves Cholestatic Markers Regardless of the Presence of Primary Biliary Cholangitis
Ryohei Tanigawa, Yoshiyuki Ueno, Hirokazu Takahashi, et al.
Journal of Clinical Lipidology
|
August 6, 2018
Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia
Shizuya Yamashita, Hidenori Arai, Koutaro Yokote, et al.
Journal of Human Genetics
|
January 7, 2005
Designing a multistage, SNP-based, genome screen for common diseases
Yasunori Sato, Hideki Suganami, Chikuma Hamada, et al.
Journal of Human Genetics
|
August 19, 2006
The confidence interval of allelic odds ratios under the Hardy-Weinberg disequilibrium
Yasunori Sato, Hideki Suganami, Chikuma Hamada, et al.
Page
of 7
Search research articles
Search
Showing results (11-20 of 70) with videos related to
Sort By:
Page
of 7
Journal of Atherosclerosis and Thrombosis
|
September 18, 2023
Long-term Efficacy and Safety of K-924 Pitavastatin/Ezetimibe Fixed-dose Combination in Patients with Hypercholesterolemia: A Phase III, Multi-center, Open-label Trial
Junya Ako, Koutaro Yokote, Kenichi Tsujita, et al.
Journal of Atherosclerosis and Thrombosis
|
April 10, 2018
Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Hidenori Arai, Shizuya Yamashita, Koutaro Yokote, et al.
Journal of Clinical Lipidology
|
December 6, 2017
Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial
Shun Ishibashi, Hidenori Arai, Koutaro Yokote, et al.
Endocrinology, Diabetes & Metabolism
|
November 21, 2023
Reductions in liver enzymes are associated with anti-hyperglycaemic and anti-obesity effects of tofogliflozin in people with type 2 diabetes: Post-hoc analyses
Toshinari Takamura, Kohei Kaku, Akihiro Yoshida, et al.
Atherosclerosis
|
April 16, 2017
Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia
Hidenori Arai, Shizuya Yamashita, Koutaro Yokote, et al.
Journal of Atherosclerosis and Thrombosis
|
March 13, 2023
Efficacy and Safety of Pitavastatin/Ezetimibe Fixed-Dose Combination vs. Pitavastatin: Phase III, Double-Blind, Randomized Controlled Trial
Kenichi Tsujita, Koutaro Yokote, Junya Ako, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
July 16, 2026
Pemafibrate Improves Cholestatic Markers Regardless of the Presence of Primary Biliary Cholangitis
Ryohei Tanigawa, Yoshiyuki Ueno, Hirokazu Takahashi, et al.
Journal of Clinical Lipidology
|
August 6, 2018
Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia
Shizuya Yamashita, Hidenori Arai, Koutaro Yokote, et al.
Journal of Human Genetics
|
January 7, 2005
Designing a multistage, SNP-based, genome screen for common diseases
Yasunori Sato, Hideki Suganami, Chikuma Hamada, et al.
Journal of Human Genetics
|
August 19, 2006
The confidence interval of allelic odds ratios under the Hardy-Weinberg disequilibrium
Yasunori Sato, Hideki Suganami, Chikuma Hamada, et al.
Page
of 7